Shift of Glucose Peak Time During Oral Glucose Tolerance Test is Associated with Changes in Insulin Secretion and Insulin Sensitivity After Therapy with Antidiabetic Drugs in Patients with Type 2 Diabetes
ConclusionExenatide, Humalog Mix25, and OADs improved glycemic metabolism. However, exenatide exhibited superior efficacy in shifting blood glucose peak time to an earlier point, while it improved insulin secretion and insulin sensitivity. Hence, the shift of glucose peak time may be considered an indicator for the evaluation of the effect of hypoglycemic drugs. (Source: Diabetes Therapy)
Source: Diabetes Therapy - August 3, 2021 Category: Endocrinology Source Type: research
Study of blood glucose and insulin infusion rate in real-time in diabetic rats using an artificial pancreas system
by Omer Batuhan Kirilmaz, Akshay Radhakrishna Salegaonkar, Justin Shiau, Guney Uzun, Hoo Sang Ko, H. Felix Lee, Sarah Park, Guim Kwon
Artificial pancreas system (APS) is an emerging new treatment for type 1 diabetes mellitus. The aim of this study was to develop a rat APS as a research tool and demonstrate its application. We established a rat APS using Medtronic Minimed Pump 722, Medtronic Enlite sensor, and the open artificial pancreas system as a controller. We tested different dilutions of Humalog (100 units/ml) in saline ranged from 1:3 to 1:20 and determined that 1:7 dilution works well for rats with ~500g bodyweigh...
Source: PLoS One - July 16, 2021 Category: Biomedical Science Authors: Omer Batuhan Kirilmaz Source Type: research
Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog ® Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data
ConclusionsAcross the studied populations and dose range, URLi consistently demonstrated a faster absorption, reduced late exposure, and overall shorter exposure duration compared with Humalog. Similarly, URLi demonstrated earlier insulin action while reducing late insulin action and shorter insulin action compared with Humalog across the study populations and dose range.Clinical Trial RegistrationNCT02942654 (registered: 21 October, 2016), NCT03286751 (registered: 15 September, 2017), NCT03166124 (registered: 23 May, 2017), and NCT03305822 (registered: 5 October, 2017). (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - May 27, 2021 Category: Drugs & Pharmacology Source Type: research
Effects of estimated glomerular filtration rate and diabetes mellitus on the effect of insulin for treating hyperkalemia during anesthesia
ConclusionThe patients with a low eGFR had a higher incidence of K+ not decreasing after insulin treatment. Periodic assessment of K+ may be required during anesthesia. (Source: Journal of Anesthesia)
Source: Journal of Anesthesia - April 16, 2021 Category: Anesthesiology Source Type: research
Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin
ConclusionsEfficacy and safety (including immunogenicity) profiles of SAR-Asp are similar to those of NN-Asp over 52 weeks in adults with diabetes irrespective of prior type of mealtime insulin.Trial RegistrationClinicalTrials.gov identifier: NCT03211858. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 11, 2021 Category: Endocrinology Source Type: research
Efficacy and safety of GP40021 insulin lispro biphasic compared with Humalog Mix 25 in Type 2 diabetes mellitus patients.
Conclusion: GP-Lis25 and Ly-Lis25 demonstrated similar safety and efficacy. ClincalTrials.gov identifier: NCT04023344.
PMID: 33355484 [PubMed - as supplied by publisher] (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - December 30, 2020 Category: General Medicine Tags: J Comp Eff Res Source Type: research
Insulin binding to the analytical antibody sandwich pair OXI ‐005 and HUI‐018: Epitope mapping and binding properties
AbstractThe insulin epitopes for two monoclonal antibodies (mAbs), OXI ‐005 and HUI‐018, commonly used in combination for insulin concentration determination in sandwich assays, were determined using X‐ray crystallography. The crystal structure of the HUI‐018 Fab in complex with human insulin (HI) was determined and OXI‐005 Fab crystal structures were determi ned in complex with HI and porcine insulin (PI) as well as on its own. The OXI‐005 epitope comprises insulin residues 1,3,4,19–21 (A‐chain) and 25–30 (B‐chain) and for HUI‐018 residues 7,8,10–14,17 (A‐chain) and 5–7, 10, 14 (B‐chain). The...
Source: Protein Science - December 15, 2020 Category: Biochemistry Authors: Eva Johansson,
Xiaoai Wu,
Bingke Yu,
Zhiru Yang,
Zheng Cao,
Charlotte Wiberg,
Claus B. Jeppesen,
Fritz Poulsen Tags: Article Source Type: research
Insulin Binding to the Analytical Antibody Sandwich Pair OXI ‐005 and HUI‐018 – Epitope Mapping and Binding Properties
This article is protected by copyright. All rights reserved. (Source: Protein Science)
Source: Protein Science - December 5, 2020 Category: Biochemistry Authors: Eva Johansson,
Xiaoai Wu,
Bingke Yu,
Zhiru Yang,
Zheng Cao,
Charlotte Wiberg,
Claus B. Jeppesen,
Fritz Poulsen Tags: Article Source Type: research
An assessment of physician reasons for prescribing Insulin Lispro 200 units/ml in Germany.
CONCLUSION: Physicians considered IL200 a promising treatment option that reduces the injection burden for patients on MTI. Physicians adopted a patient-centered perspective by aligning IL200 prescribing decisions with each patient's medical needs and non-clinical preferences, with an aim to encourage treatment adherence through resorting to IL200's advantageous attributes.
PMID: 33108957 [PubMed - as supplied by publisher] (Source: Postgraduate Medicine)
Source: Postgraduate Medicine - October 29, 2020 Category: Internal Medicine Tags: Postgrad Med Source Type: research
Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease
Conclusion: Exenatide plus insulin glargine treatment for 24 weeks resulted in a reduction of albuminuria in T2DM patients with DKD.Am J Nephrol (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 23, 2020 Category: Neurology Source Type: research
Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease.
CONCLUSION: Exenatide plus insulin glargine treatment for 24 weeks resulted in a reduction of albuminuria in T2DM patients with DKD.
PMID: 32966971 [PubMed - as supplied by publisher] (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 22, 2020 Category: Urology & Nephrology Authors: Wang X, Zhang H, Zhang Q, Guan M, Sheng S, Mo W, Zou M, Li J, Bi J, Tang X, Zeng H, He J, Xu G, Li P, Xue Y Tags: Am J Nephrol Source Type: research
Lyumjev - A New Insulin Lispro for Diabetes
Date: October 19, 2020
Issue #:
1609Summary:
The FDA has approved insulin lispro-aabc (Lyumjev–
Lilly), a faster-acting formulation of insulin lispro(Humalog), for treatment of type 1 and type 2 diabetes
in adults.Fiasp, a faster-acting formulation of insulin
aspart(Novolog), was approved in 2017. (Source: The Medical Letter)
Source: The Medical Letter - September 14, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research
Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro (URLi) vs Lispro (Humalog ®) Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects.
This study compared the pharmacokinetic and glucodynamic parameters of URLi and Lispro (Humalog®) at 3 dose levels in healthy subjects.
METHODS: This randomized, 6-period, subject- and investigator-blind, crossover study included 42 healthy subjects. At each period, subjects received a single subcutaneous dose of 7, 15, or 30 U of URLi or Lispro followed by a 10-h automated euglycemic clamp. Insulin lispro and blood glucose concentrations were measured.
FINDINGS: Across all 3 doses, insulin lispro appeared in the serum 2-5 min faster, and exposure was 6- to 8-fold greater in the first 15 min, with URLi v...
Source: Clinical Therapeutics - September 4, 2020 Category: Drugs & Pharmacology Authors: Leohr J, Dellva MA, LaBell E, Coutant DE, Klein O, Plum-Moerschel L, Zijlstra E, Linnebjerg H Tags: Clin Ther Source Type: research
Patient characteristics of insulin lispro 200 Units/mL users in real world setting in Germany.
Conclusions: IL200 is prescribed to people with diabetes who need more than 20 U/day of mealtime insulin and tend to be more obese, older, and with multiple comorbidities. Future research should explore how concentrated MTI can impact adherence and long-term glycemia.
PMID: 32845743 [PubMed - as supplied by publisher] (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - August 29, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research
